- Pre-clinical evaluation of the hypomethylating agent decitabine for the treatment of T-cell lymphoblastic lymphoma(2023)
Auteurs: Tom Putteman, Mattias Landfors, Lindy Reunes, Wouter Van Loocke, Morgan Thenoz, Natalia Mackowska-Maslak, Tom Taghon, Marc R. Mansour, Nadine Farah, Koen Norga, et al.
- Direct and indirect anti-leukemic properties of Activity-on-Target interferons for the treatment of T-cell acute lymphoblastic leukemia(2022)
Auteurs: Renate De Smedt, Willem Daneels, Pieter Van Vlierberghe, Jan Tavernier
Pagina's: 1448 - 1453
- Finding the 'key' in leukemia : PIM1 inhibition as a novel therapy in T-cell acute lymphoblastic leukemia(2020)
Auteurs: Renate De Smedt
- Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma(2020)
Auteurs: Renate De Smedt, Julie Morscio, Lindy Reunes, Juliette Roels, Valentina Bardelli, Béatrice Lintermans, Wouter Van Loocke, Afonso Almeida, Laurence C. Cheung, Rishi S. Kotecha, et al.
Pagina's: 1685 - 1695
- Targeting steroid resistance in T-cell acute lymphoblastic leukemia(2019)
Auteurs: Renate De Smedt, Julie Morscio, Steven Goossens, Pieter Van Vlierberghe
- Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma(2018)
Auteurs: Renate De Smedt, Sofie Peirs, Julie Morscio, Filip Matthijssens, Juliette Roels, Lindy Reunes, Béatrice Lintermans, Steven Goossens, Tim Lammens, Nadine Van Roy, et al.
Pagina's: e17 - e20